logo
Plus   Neg
Share
Email

AVITA Medical Launches RECELL System For Acute Thermal Burns In U.S.; Stock Up

Shares of AVITA Medical (AVH.AX, AVMXY) were gaining around 5 percent in Australian trading as the regenerative medicine company announced that it has commenced the U.S. national market launch of the RECELL Autologous Cell Harvesting Device or RECELL System for the treatment of acute thermal burns in patients 18 years and older.

The U.S. sales team of Regenerative Tissue Specialists and Clinical Training Specialists that joined AVITA Medical in November 2018 has been trained and fully deployed across the U.S. in support of the nationwide launch of the RECELL System.

In advance of the national launch, AVITA Medical has been actively fulfilling orders in response to strong market demand. AVITA said its new commercial team is now in active discussions with nearly half of the total number of burn centers across the U.S.

The company also announced the successful commercial results that have been achieved in advance of the national market launch. The company said 36 burns centers have begun the purchase authorization process with their hospital administration, 25 burn centers have been trained and certified in the use of the RECELL System, and 12 accounts have already placed orders and have received commercial shipments.

For comments and feedback contact: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
MillerCoors LLC has filed a lawsuit against Anheuser-Busch Companies LLC, part of Anheuser-Busch InBev, alleging that Anheuser-Busch's ad campaigns associating MillerCoors' products, Miller Lite and Coor Light, with corn syrup is "false and misleading." During the Super Bowl, ABInBev ran an advertising campaign that mocked Miller Lite and Coors Light use corn syrup in brewing. Shares of Biogen Inc. are falling almost 28 percent in Thursday's trading after the company and Japanese drugmaker Eisai Co. said they will discontinue two late-stage trials for their experimental Alzheimer's drug, Aducanumab. The two Phase 3 trials, ENGAGE and EMERGE, are multi-center, randomized, double-blind, placebo-controlled, parallel-group studies designed to evaluate Aducanumab. The European Union on Wednesday ordered Alphabet Inc.'s Google to pay an antitrust fine of 1.49 billion euros for abusing its dominant position in the online search advertising intermediation market by preventing competition. This is the third antitrust fine by the EU against Google and it represents 1.29 percent of the tech giant's turnover in 2018.
Follow RTT